Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "ANLOTINIB HYDROCHLORIDE CAPSULES" OBTAINS APPROVAL FOR THIRD INDICATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take

no responsibility for the contents of this announcement, make no representation as to its accuracy or

completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in

reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"ANLOTINIB HYDROCHLORIDE CAPSULES" OBTAINS APPROVAL FOR THIRD INDICATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that "Anlotinib Hydrochloride Capsules" (brand name "FOCUS V®"), an antitumor drug self-developed by Chia Tai-Tianqing Pharmaceutical Group Co., Ltd, a subsidiary of the Company, has obtained the approval for drug registration granted by the National Medical Products Administration of the People's Republic of China, for a new indication for "third- line treatment of small cell lung cancer". It is the third indication that Anlotinib Hydrochloride Capsules obtains approval, after it was approved to treat advanced non-small cell lung cancer and soft tissue sarcoma in the last year and June this year, respectively.

For clinical treatment of small cell lung cancer, the current standard first-line treatment is combination chemotherapy of etoposide plus platinum-based drugs which has struggled in progress of efficacy for over two decades. The second-line treatment is topotecan chemotherapy which is yet to attain satisfactory result. New medicine is desperately needed for the treatment of small cell lung cancer. Anlotinib Hydrochloride is a receptor tyrosine kinase inhibitor of multi-targets, with anti-tumor angiogenesis and tumor growth inhibition actions. The efficacy of Anlotinib Hydrochloride for the third- line treatment of small cell lung cancer has been clinically confirmed. The clinical effectiveness analysis indicates that, compared with the placebo group, the progression-free survival of patients of small cell lung cancer who were treated with Anlotinib Hydrochloride was significantly extended.

The Group has always been actively responding to the government's call and striving to reduce the medication burden of domestic cancer patients. The pricing of FOCUS V is only 50%-60% of similar imported drugs, with the characteristics of small dosage and convenience for medication. Since its launch last year, FOCUS V has reduced pain, prevented loss of life and improved the quality of life for countless cancer patients. It also offers more medical options to clinical doctors. FOCUS V is attached with positive social significance and has a broad market prospect.

1

By Order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairlady

Hong Kong, 4 September 2019

As at the date of this announcement, the Board of the Company comprises seven Executive Directors, namely Miss Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.

2